<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fasching, Peter</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">In Real-World Settings, EVE and EXE Extend PFS in Breast Cancer: BRAWO</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-22</style></pages><abstract><style  face="normal" font="default" size="100%">Administration of everolimus (combined with exemestane in real-world conditions extends progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer. Data from the German Breast Cancer Treatment With Afinitor (Everolimus) and Exemestane for ER+ Women trial [BRAWO] are discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>